Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Market Overview
1.1 Oncolytic Virus Therapy Product Introduction
1.2 Global Oncolytic Virus Therapy Market Size Forecast (2020-2031)
1.3 Oncolytic Virus Therapy Market Trends & Drivers
1.3.1 Oncolytic Virus Therapy Industry Trends
1.3.2 Oncolytic Virus Therapy Market Drivers & Opportunity
1.3.3 Oncolytic Virus Therapy Market Challenges
1.3.4 Oncolytic Virus Therapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Oncolytic Virus Therapy Players Revenue Ranking (2024)
2.2 Global Oncolytic Virus Therapy Revenue by Company (2020-2025)
2.3 Key Companies Oncolytic Virus Therapy Manufacturing Base Distribution and Headquarters
2.4 Key Companies Oncolytic Virus Therapy Product Offered
2.5 Key Companies Time to Begin Mass Production of Oncolytic Virus Therapy
2.6 Oncolytic Virus Therapy Market Competitive Analysis
2.6.1 Oncolytic Virus Therapy Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Oncolytic Virus Therapy Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 HSV-based Oncolytic Viruses
3.1.2 Adenoviruses-based Oncolytic Viruses
3.1.3 Vaccinia Virus-based Oncolytic Viruses
3.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
3.1.5 Newcastle Disease Virus-based Oncolytic Viruses
3.2 Global Oncolytic Virus Therapy Sales Value by Type
3.2.1 Global Oncolytic Virus Therapy Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Oncolytic Virus Therapy Sales Value, by Type (2020-2031)
3.2.3 Global Oncolytic Virus Therapy Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Melanoma
4.1.2 Prostate Cancer
4.1.3 Breast Cancer
4.1.4 Ovarian Cancer
4.1.5 Others
4.2 Global Oncolytic Virus Therapy Sales Value by Application
4.2.1 Global Oncolytic Virus Therapy Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Oncolytic Virus Therapy Sales Value, by Application (2020-2031)
4.2.3 Global Oncolytic Virus Therapy Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Oncolytic Virus Therapy Sales Value by Region
5.1.1 Global Oncolytic Virus Therapy Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Oncolytic Virus Therapy Sales Value by Region (2020-2025)
5.1.3 Global Oncolytic Virus Therapy Sales Value by Region (2026-2031)
5.1.4 Global Oncolytic Virus Therapy Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Oncolytic Virus Therapy Sales Value, 2020-2031
5.2.2 North America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
5.3.2 Europe Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Oncolytic Virus Therapy Sales Value, 2020-2031
5.4.2 Asia Pacific Oncolytic Virus Therapy Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Oncolytic Virus Therapy Sales Value, 2020-2031
5.5.2 South America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Oncolytic Virus Therapy Sales Value, 2020-2031
5.6.2 Middle East & Africa Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Oncolytic Virus Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Oncolytic Virus Therapy Sales Value, 2020-2031
6.3 United States
6.3.1 United States Oncolytic Virus Therapy Sales Value, 2020-2031
6.3.2 United States Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Oncolytic Virus Therapy Sales Value, 2020-2031
6.4.2 Europe Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Oncolytic Virus Therapy Sales Value, 2020-2031
6.5.2 China Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
6.5.3 China Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Oncolytic Virus Therapy Sales Value, 2020-2031
6.6.2 Japan Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Oncolytic Virus Therapy Sales Value, 2020-2031
6.7.2 South Korea Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Oncolytic Virus Therapy Sales Value, 2020-2031
6.8.2 Southeast Asia Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Oncolytic Virus Therapy Sales Value, 2020-2031
6.9.2 India Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
6.9.3 India Oncolytic Virus Therapy Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Amgen
7.1.1 Amgen Profile
7.1.2 Amgen Main Business
7.1.3 Amgen Oncolytic Virus Therapy Products, Services and Solutions
7.1.4 Amgen Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.1.5 Amgen Recent Developments
7.2 Oncolytics Biotech
7.2.1 Oncolytics Biotech Profile
7.2.2 Oncolytics Biotech Main Business
7.2.3 Oncolytics Biotech Oncolytic Virus Therapy Products, Services and Solutions
7.2.4 Oncolytics Biotech Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.2.5 Oncolytics Biotech Recent Developments
7.3 Viralytics
7.3.1 Viralytics Profile
7.3.2 Viralytics Main Business
7.3.3 Viralytics Oncolytic Virus Therapy Products, Services and Solutions
7.3.4 Viralytics Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.3.5 Viralytics Recent Developments
7.4 Transgene SA
7.4.1 Transgene SA Profile
7.4.2 Transgene SA Main Business
7.4.3 Transgene SA Oncolytic Virus Therapy Products, Services and Solutions
7.4.4 Transgene SA Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.4.5 Transgene SA Recent Developments
7.5 Oncolys BioPharma
7.5.1 Oncolys BioPharma Profile
7.5.2 Oncolys BioPharma Main Business
7.5.3 Oncolys BioPharma Oncolytic Virus Therapy Products, Services and Solutions
7.5.4 Oncolys BioPharma Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.5.5 Oncolys BioPharma Recent Developments
7.6 Targovax
7.6.1 Targovax Profile
7.6.2 Targovax Main Business
7.6.3 Targovax Oncolytic Virus Therapy Products, Services and Solutions
7.6.4 Targovax Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.6.5 Targovax Recent Developments
7.7 PsiOxus Therapeutics
7.7.1 PsiOxus Therapeutics Profile
7.7.2 PsiOxus Therapeutics Main Business
7.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Products, Services and Solutions
7.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.7.5 PsiOxus Therapeutics Recent Developments
7.8 SillaJen Biotherapeutics
7.8.1 SillaJen Biotherapeutics Profile
7.8.2 SillaJen Biotherapeutics Main Business
7.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Products, Services and Solutions
7.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.8.5 SillaJen Biotherapeutics Recent Developments
7.9 Sorrento Therapeutics
7.9.1 Sorrento Therapeutics Profile
7.9.2 Sorrento Therapeutics Main Business
7.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Products, Services and Solutions
7.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.9.5 Sorrento Therapeutics Recent Developments
7.10 Lokon Pharma
7.10.1 Lokon Pharma Profile
7.10.2 Lokon Pharma Main Business
7.10.3 Lokon Pharma Oncolytic Virus Therapy Products, Services and Solutions
7.10.4 Lokon Pharma Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.10.5 Lokon Pharma Recent Developments
7.11 Genelux Corporation
7.11.1 Genelux Corporation Profile
7.11.2 Genelux Corporation Main Business
7.11.3 Genelux Corporation Oncolytic Virus Therapy Products, Services and Solutions
7.11.4 Genelux Corporation Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.11.5 Genelux Corporation Recent Developments
7.12 Vyriad
7.12.1 Vyriad Profile
7.12.2 Vyriad Main Business
7.12.3 Vyriad Oncolytic Virus Therapy Products, Services and Solutions
7.12.4 Vyriad Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.12.5 Vyriad Recent Developments
7.13 TILT Biotherapeutics
7.13.1 TILT Biotherapeutics Profile
7.13.2 TILT Biotherapeutics Main Business
7.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Products, Services and Solutions
7.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.13.5 TILT Biotherapeutics Recent Developments
7.14 Cold Genesys
7.14.1 Cold Genesys Profile
7.14.2 Cold Genesys Main Business
7.14.3 Cold Genesys Oncolytic Virus Therapy Products, Services and Solutions
7.14.4 Cold Genesys Oncolytic Virus Therapy Revenue (US$ Million) & (2020-2025)
7.14.5 Cold Genesys Recent Developments
8 Industry Chain Analysis
8.1 Oncolytic Virus Therapy Industrial Chain
8.2 Oncolytic Virus Therapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Oncolytic Virus Therapy Sales Model
8.5.2 Sales Channel
8.5.3 Oncolytic Virus Therapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

List of Tables
Table 1. Oncolytic Virus Therapy Market Trends
Table 2. Oncolytic Virus Therapy Market Drivers & Opportunity
Table 3. Oncolytic Virus Therapy Market Challenges
Table 4. Oncolytic Virus Therapy Market Restraints
Table 5. Global Oncolytic Virus Therapy Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Oncolytic Virus Therapy Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Oncolytic Virus Therapy Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Oncolytic Virus Therapy Product Type
Table 9. Key Companies Time to Begin Mass Production of Oncolytic Virus Therapy
Table 10. Global Oncolytic Virus Therapy Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Oncolytic Virus Therapy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Oncolytic Virus Therapy Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Oncolytic Virus Therapy Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Oncolytic Virus Therapy Sales Market Share in Value by Type (2020-2025)
Table 17. Global Oncolytic Virus Therapy Sales Market Share in Value by Type (2026-2031)
Table 18. Global Oncolytic Virus Therapy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Oncolytic Virus Therapy Sales Value by Application (2020-2025) & (US$ Million)
Table 20. Global Oncolytic Virus Therapy Sales Value by Application (2026-2031) & (US$ Million)
Table 21. Global Oncolytic Virus Therapy Sales Market Share in Value by Application (2020-2025)
Table 22. Global Oncolytic Virus Therapy Sales Market Share in Value by Application (2026-2031)
Table 23. Global Oncolytic Virus Therapy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 24. Global Oncolytic Virus Therapy Sales Value by Region (2020-2025) & (US$ Million)
Table 25. Global Oncolytic Virus Therapy Sales Value by Region (2026-2031) & (US$ Million)
Table 26. Global Oncolytic Virus Therapy Sales Value by Region (2020-2025) & (%)
Table 27. Global Oncolytic Virus Therapy Sales Value by Region (2026-2031) & (%)
Table 28. Key Countries/Regions Oncolytic Virus Therapy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 29. Key Countries/Regions Oncolytic Virus Therapy Sales Value, (2020-2025) & (US$ Million)
Table 30. Key Countries/Regions Oncolytic Virus Therapy Sales Value, (2026-2031) & (US$ Million)
Table 31. Amgen Basic Information List
Table 32. Amgen Description and Business Overview
Table 33. Amgen Oncolytic Virus Therapy Products, Services and Solutions
Table 34. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Amgen (2020-2025)
Table 35. Amgen Recent Developments
Table 36. Oncolytics Biotech Basic Information List
Table 37. Oncolytics Biotech Description and Business Overview
Table 38. Oncolytics Biotech Oncolytic Virus Therapy Products, Services and Solutions
Table 39. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Oncolytics Biotech (2020-2025)
Table 40. Oncolytics Biotech Recent Developments
Table 41. Viralytics Basic Information List
Table 42. Viralytics Description and Business Overview
Table 43. Viralytics Oncolytic Virus Therapy Products, Services and Solutions
Table 44. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Viralytics (2020-2025)
Table 45. Viralytics Recent Developments
Table 46. Transgene SA Basic Information List
Table 47. Transgene SA Description and Business Overview
Table 48. Transgene SA Oncolytic Virus Therapy Products, Services and Solutions
Table 49. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Transgene SA (2020-2025)
Table 50. Transgene SA Recent Developments
Table 51. Oncolys BioPharma Basic Information List
Table 52. Oncolys BioPharma Description and Business Overview
Table 53. Oncolys BioPharma Oncolytic Virus Therapy Products, Services and Solutions
Table 54. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Oncolys BioPharma (2020-2025)
Table 55. Oncolys BioPharma Recent Developments
Table 56. Targovax Basic Information List
Table 57. Targovax Description and Business Overview
Table 58. Targovax Oncolytic Virus Therapy Products, Services and Solutions
Table 59. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Targovax (2020-2025)
Table 60. Targovax Recent Developments
Table 61. PsiOxus Therapeutics Basic Information List
Table 62. PsiOxus Therapeutics Description and Business Overview
Table 63. PsiOxus Therapeutics Oncolytic Virus Therapy Products, Services and Solutions
Table 64. Revenue (US$ Million) in Oncolytic Virus Therapy Business of PsiOxus Therapeutics (2020-2025)
Table 65. PsiOxus Therapeutics Recent Developments
Table 66. SillaJen Biotherapeutics Basic Information List
Table 67. SillaJen Biotherapeutics Description and Business Overview
Table 68. SillaJen Biotherapeutics Oncolytic Virus Therapy Products, Services and Solutions
Table 69. Revenue (US$ Million) in Oncolytic Virus Therapy Business of SillaJen Biotherapeutics (2020-2025)
Table 70. SillaJen Biotherapeutics Recent Developments
Table 71. Sorrento Therapeutics Basic Information List
Table 72. Sorrento Therapeutics Description and Business Overview
Table 73. Sorrento Therapeutics Oncolytic Virus Therapy Products, Services and Solutions
Table 74. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Sorrento Therapeutics (2020-2025)
Table 75. Sorrento Therapeutics Recent Developments
Table 76. Lokon Pharma Basic Information List
Table 77. Lokon Pharma Description and Business Overview
Table 78. Lokon Pharma Oncolytic Virus Therapy Products, Services and Solutions
Table 79. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Lokon Pharma (2020-2025)
Table 80. Lokon Pharma Recent Developments
Table 81. Genelux Corporation Basic Information List
Table 82. Genelux Corporation Description and Business Overview
Table 83. Genelux Corporation Oncolytic Virus Therapy Products, Services and Solutions
Table 84. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Genelux Corporation (2020-2025)
Table 85. Genelux Corporation Recent Developments
Table 86. Vyriad Basic Information List
Table 87. Vyriad Description and Business Overview
Table 88. Vyriad Oncolytic Virus Therapy Products, Services and Solutions
Table 89. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Vyriad (2020-2025)
Table 90. Vyriad Recent Developments
Table 91. TILT Biotherapeutics Basic Information List
Table 92. TILT Biotherapeutics Description and Business Overview
Table 93. TILT Biotherapeutics Oncolytic Virus Therapy Products, Services and Solutions
Table 94. Revenue (US$ Million) in Oncolytic Virus Therapy Business of TILT Biotherapeutics (2020-2025)
Table 95. TILT Biotherapeutics Recent Developments
Table 96. Cold Genesys Basic Information List
Table 97. Cold Genesys Description and Business Overview
Table 98. Cold Genesys Oncolytic Virus Therapy Products, Services and Solutions
Table 99. Revenue (US$ Million) in Oncolytic Virus Therapy Business of Cold Genesys (2020-2025)
Table 100. Cold Genesys Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Oncolytic Virus Therapy Downstream Customers
Table 104. Oncolytic Virus Therapy Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts


List of Figures
Figure 1. Oncolytic Virus Therapy Product Picture
Figure 2. Global Oncolytic Virus Therapy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Oncolytic Virus Therapy Sales Value (2020-2031) & (US$ Million)
Figure 4. Oncolytic Virus Therapy Report Years Considered
Figure 5. Global Oncolytic Virus Therapy Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Oncolytic Virus Therapy Revenue in 2024
Figure 7. Oncolytic Virus Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. HSV-based Oncolytic Viruses Picture
Figure 9. Adenoviruses-based Oncolytic Viruses Picture
Figure 10. Vaccinia Virus-based Oncolytic Viruses Picture
Figure 11. Vesicular Stomatitis Virus-based Oncolytic Viruses Picture
Figure 12. Newcastle Disease Virus-based Oncolytic Viruses Picture
Figure 13. Global Oncolytic Virus Therapy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 14. Global Oncolytic Virus Therapy Sales Value Market Share by Type, 2024 & 2031
Figure 15. Product Picture of Melanoma
Figure 16. Product Picture of Prostate Cancer
Figure 17. Product Picture of Breast Cancer
Figure 18. Product Picture of Ovarian Cancer
Figure 19. Product Picture of Others
Figure 20. Global Oncolytic Virus Therapy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 21. Global Oncolytic Virus Therapy Sales Value Market Share by Application, 2024 & 2031
Figure 22. North America Oncolytic Virus Therapy Sales Value (2020-2031) & (US$ Million)
Figure 23. North America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
Figure 24. Europe Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 25. Europe Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
Figure 26. Asia Pacific Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 27. Asia Pacific Oncolytic Virus Therapy Sales Value by Region (%), 2024 VS 2031
Figure 28. South America Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 29. South America Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
Figure 30. Middle East & Africa Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 31. Middle East & Africa Oncolytic Virus Therapy Sales Value by Country (%), 2024 VS 2031
Figure 32. Key Countries/Regions Oncolytic Virus Therapy Sales Value (%), (2020-2031)
Figure 33. United States Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 34. United States Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
Figure 35. United States Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
Figure 36. Europe Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 37. Europe Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
Figure 38. Europe Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
Figure 39. China Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 40. China Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
Figure 41. China Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
Figure 42. Japan Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 43. Japan Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
Figure 44. Japan Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
Figure 45. South Korea Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 46. South Korea Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
Figure 47. South Korea Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
Figure 48. Southeast Asia Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 49. Southeast Asia Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
Figure 50. Southeast Asia Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
Figure 51. India Oncolytic Virus Therapy Sales Value, (2020-2031) & (US$ Million)
Figure 52. India Oncolytic Virus Therapy Sales Value by Type (%), 2024 VS 2031
Figure 53. India Oncolytic Virus Therapy Sales Value by Application (%), 2024 VS 2031
Figure 54. Oncolytic Virus Therapy Industrial Chain
Figure 55. Oncolytic Virus Therapy Manufacturing Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed